ArticleNPJ Parkinson's disease2026
Magnetoencephalography-based prediction of longitudinal symptom progression in Parkinson's disease.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pursuit of biomarkers of brain diseases: beyond cohort comparisons.NPJ digital medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Motor dysfunction in Parkinson's disease (PD) has been linked to widespread oscillatory changes within the basal ganglia-thalamic-cortical network, particularly in the beta frequency range. However, the evolution of cortical neurophysiological alterations and their relationship to clinical progression remain poorly understood. We conducted a longitudinal resting-state magnetoencephalography (MEG) study in 27 persons with PD and 30 healthy individuals with a mean follow-up time of 4 years. Source-reconstructed MEG data were parcellated into cortical regions, from which power spectra were parameterized to separate oscillatory peaks from the aperiodic component. An increase in the aperiodic exponent in the left postcentral region was associated with progression of rigidity. Peak beta power in parieto-temporo-occipital regions was elevated at baseline, correlating with less severe bradykinesia. This negative relationship weakened over time in patients with progressive symptoms, suggesting an association with compensatory mechanisms. Using partial least squares regression to predict future disease course from baseline neurophysiological features, 19.5% of the variability in motor progression was explained in an independent validation cohort. Our results emphasize the importance of separating aperiodic neural activity from periodic oscillations as a progressive alteration of the aperiodic component represented the most prominent PD-related neurophysiological change. Further, our findings highlight the potential predictive value of resting-state neurophysiology for future disease progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.